News

January 7, 2019January 7, 2019

Simponi Lowers Incidence of Acute Anterior Uveitis, Phase 4 Study Shows

News

Treatment with Simponi (golimumab) reduced the incidence of a type of eye inflammation called acute anterior uveitis (AAU) and decreased disease activity in patients with ankylosing spondylitis (AS), according ... Read more

January 2, 2019January 2, 2019

Novartis, TrialSpark Collaborate to Maximize Patient Access to Clinical Trials, Therapy Development

News

TrialSpark, a technology company that works to increase access and integrate trial participation into patients’ everyday lives, has teamed up with Novartis, a global healthcare company, to activate their first clinical ... Read more

December 20, 2018December 20, 2018

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

News

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to ... Read more

December 3, 2018December 3, 2018

TNF-alpha Inhibitors May Increase Eosinophil Levels in Ankylosing Spondylitis Patients, Study Suggests

News

Use of TNF-alpha inhibitors reduces inflammation and increases levels of eosinophils — a type of immune cell that protects the body from infections — in patients with ankylosing spondylitis, ... Read more

November 26, 2018November 26, 2018

Genetic Marker HLA-B27 Correlates With Ankylosing Spondylitis Onset but Not Disease Burden, Study Shows

News

The presence of a specific genetic marker called HLA-B27 in Caucasian ankylosing spondylitis patients is related to earlier disease onset and higher disease prevalence among family members, a study has found. However, ... Read more

November 12, 2018November 12, 2018

Phase 3 Trial Evaluating Xeljanz’s Efficacy in Patients with Active Ankylosing Spondylitis Now Enrolling

News

Pfizer is recruiting adult patients with active ankylosing spondylitis for a new Phase 3 clinical trial to evaluate the safety and therapeutic activity of Xeljanz (tofacitinib). The study (NCT03502616) is expected ... Read more

November 5, 2018November 5, 2018

Ixekizumab Benefits Ankylosing Spondylitis Patients Who Failed to Respond to Standard Therapy, Phase 3 Study Shows

News

Ankylosing spondylitis (AS) patients who have failed to respond to standard therapy may benefit from treatment with ixekizumab (Taltz by Eli Lilly), Phase 3 study results show. The study, ... Read more

October 31, 2018October 29, 2018

#NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach

News

With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand ... Read more

October 29, 2018October 29, 2018

Anti-Rheumatic or Anti-Tumor Necrosis Therapy Does Not Contribute to Increased Infection Risk, Study Shows

News

Patients with ankylosing spondylitis treated with anti-rheumatic drugs or anti-tumor necrosis therapy are not more likely to develop infections compared to non-users, a study shows. The study, “Use of ... Read more

October 24, 2018October 24, 2018

Filgotinib Safe, Effective in Treating Ankylosing Spondylitis, Phase 2 Trial Shows

News

Filgotinib, an investigational therapy for ankylosing spondylitis (AS) and other inflammatory diseases, was able to significantly reduce disease activity, according to recent Phase 2 clinical trial results announced by Gilead Sciences ... Read more

Pin It on Pinterest